On July 23 and 24, 2026, the Federal Drug Administration’s (“FDA”) Pharmacy Compounding Advisory Committee voted to recommend that six popular peptides be added to the 503A Bulks List. These include BPC-157, KPV, TB-500, MOTS-C, Epitalon, and Semax. The committee declined to recommend a seventh peptide, emideltide, for inclusion on the list.
The committee’s vote is only advisory, and the agency will now review the recommendations and determine whether to proceed with the rulemaking process necessary to formally add the six peptides to the 503A Bulks List. Until that process is completed, the regulatory status of these peptides remains unchanged.
For now, providers should not assume that these compounds are FDA-approved or that prescribing and compounding restrictions have changed. The FDA Advisory Committee’s vote is an important development, but it does not immediately change the legal status of these peptides.
If ultimately approved by the FDA, the recommendation would permit licensed 503A compounding pharmacies to compound these substances for individual patients when there is a patient-specific prescription.
Why the FDA Revisited Compounded Peptides
The vote follows years of regulatory uncertainty surrounding peptides. In 2023, the FDA identified many of these peptides as presenting safety concerns and restricted their use in traditional pharmacy compounding. Supporters of broader peptide access argued that these restrictions did not eliminate consumer demand, but instead pushed many individuals toward unregulated domestic and overseas suppliers, raising concerns about product quality, sterility, and authenticity. As interest in peptide therapies continued to grow, the FDA initiated a re-evaluation process to determine whether these drugs should be eligible for compounding under Section 503A. Although inclusion on the 503A Bulks List would expand access to these peptides, important limitations would remain.
How Adding Peptides to the 503A Bulks List Could Affect Health Care Practices
Unlike FDA-registered 503B outsourcing facilities which can compound in bulk, 503A pharmacies generally may compound medications only after receiving a valid prescription for a particular patient.
Health Care Practices Still Cannot Purchase Compounded Peptides in Bulk
Even if these peptides are added to the 503A Bulks List, medical spas, wellness clinics, and physician practices generally would not be permitted to purchase these compounded peptide products in bulk for office stock or general use. Instead, each compounded preparation would need to be linked to a specific patient’s prescription and medical needs.
Adding Peptides to the 503A Bulks List Would Not Make Them FDA Approved
Placement on the list would not make these peptides FDA approved or establish that they are safe or effective for any particular use. Instead, it would allow licensed 503A compounders to prepare patient-specific formulations using these bulk drug substances when permitted under applicable federal and state law.
While inclusion on the 503A Bulks List could expand access to compounded peptides, it would not eliminate the legal and regulatory considerations that come with offering them in a practice.
What Practices Should Evaluate When Offering Peptides
If these peptides are added to the 503A Bulks List, physicians and wellness practices should not view the change as a green light to expand peptide services without further review. Since federal and state requirements would continue to apply, providers should evaluate how peptide-related services align with their existing compliance obligations, including:
- Standard of Care requirements and potential medical board or malpractice risks
- State Complementary and Alternative Medicine (“CAM”) limitations
- Patient-specific prescriptions requirements
- 503A pharmacy compounding limitations
- Office stock restrictions
- Patient consent and medical necessity documentation requirements
- Marketing and advertising claims involving compounded peptides
- Insurance coverage and reimbursement considerations
How ByrdAdatto Helps Health Care Practices Navigate Peptide Compliance
Health care practices offering or considering peptide therapies should carefully assess the compliance requirements associated with prescribing, compounding, purchasing, documenting, and marketing peptides. Even if the FDA ultimately adopts the advisory committee’s recommendation, providers will still need to navigate federal and state requirements.
Every business decision carries legal and regulatory considerations. ByrdAdatto helps health care practice owners identify potential risks, understand applicable requirements, and develop a compliant strategy that supports your practice goals. Contact ByrdAdatto to learn whether our approach is a good fit for your practice.
